Insmed

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Insmed reports robust earnings, eyes pipeline expansion and regulatory support

Insmed's strong financial performance in 2022, driven by ARIKAYCE revenue and prudent cost management, sets a solid foundation for future growth. The company's focus on pipeline expansion, regulatory enthusiasm for brensocatib, and strategic milestones position it well for success. Challenges in the NTM market and pandemic-related impacts require careful navigation, but opportunities in new trials and gene therapy offer promising avenues for growth.

Insmed excels in Q1 with revenue growth and trial milestones

Insmed's strong Q1 performance driven by revenue growth and successful trial enrollments.
Challenges include regulatory differences and unblinding requirements for trial outcomes.
Opportunities lie in expanding ARIKAYCE's market reach and showcasing research efforts.
Financial stability and positive program reviews position Insmed well for future growth.

Insmed achieves record sales, strengthens capabilities in untreatable diseases

Insmed's Q2 2023 performance reflects robust sales growth, improved financial stability, and strategic acquisitions, positioning the company for future success.
The company's strengths lie in its commercial performance, innovative treatment formulations, and enhanced capabilities in synthetic rescue for untreatable diseases.
While facing challenges in clinical trial success and financial management, Insmed has opportunities to leverage its R&D portfolio, expedite drug approvals, and drive growth in key therapeutic areas.

Insmed reports record revenues and advances in trials, poised for growth

Insmed's Q3 2023 performance reflects record revenues for ARIKAYCE and positive trial results for brensocatib, positioning the company for continued growth.
Strong cash reserves, successful commercial activities, and promising trial data highlight Insmed's strengths and potential for future success in the biopharmaceutical market.
While facing funding challenges and trial complexities, Insmed has opportunities to leverage trial outcomes, enhance treatment efficacy, and secure financing for growth.
Overall, Insmed's strategic focus on product performance, financial stability, and innovation underscores its commitment to advancing therapies and driving shareholder value.

Insmed reports strong earnings, projects brensocatib sales exceeding $5B

Insmed's Q4 2023 earnings call highlighted strong financial performance, positive trial results, and strategic initiatives to maintain cash balance and drive commercial opportunities
The company's focus on patient-centric approaches, diverse early-stage assets, and opportunities for label expansion and commercial success position Insmed for future growth
While facing challenges related to placebo effects, regulatory requirements, and therapeutic advancements, Insmed's emphasis on reducing exacerbation rates and pursuing innovative therapies presents avenues for overcoming obstacles
With a robust cash position, promising pipeline developments, and a clear commercial outlook, Insmed demonstrates resilience and potential for market impact in the biopharmaceutical industry

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Insmed Incorporated's (INSM) CEO Will Lewis on Q4 2021 Results - Earnings Call Transcript

Insmed (INSM) delivered earnings and revenue surprises of -6.74% and 10.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates

BRIDGEWATER, N.J., Feb. 17, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on the Company's business and pipeline.

Insmed Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business and Pipeline Update

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BRIDGEWATER, N.J., Feb. 10, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the SVB Leerink Virtual 11th Annual Global Healthcare Conference on February 18, 2022 at 10:00 a.m.

Insmed To Present at the SVB Leerink Virtual 11th Annual Global Healthcare Conference

Eleison Pharmaceuticals acquires, develops and commercializes late-stage therapies for orphan diseases with unmet needs. The Company's three pipeline candidates have received the Orphan Drug Designation by the FDA, and two of them also from the EMA.

Eleison Pharmaceuticals: Betting On Late-Stage Candidates For Orphan Diseases

BRIDGEWATER, N.J., Jan. 27, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth quarter and full year 2021 financial results on Thursday, February 17, 2022.

Insmed to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Provide a Business and Pipeline Update on Thursday, February 17, 2022

BRIDGEWATER, N.J., Jan. 4, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the virtual 40th Annual J.P.

Insmed To Present at the 40th Annual J.P. Morgan Healthcare Conference

BRIDGEWATER, N.J., Nov. 3, 2021 /PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following virtual investor conferences: The Credit Suisse 30th Annual Virtual Healthcare Conference on November 9, 2021 at 10:30 a.m.

Insmed To Participate in Three November Conferences

BRIDGEWATER, N.J., Oct. 28, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it has ranked as the top company to work for in Science's 2021 Top Employers Survey.

Insmed Ranks No. 1 on Science's 2021 Top Biopharma Employers List

Insmed Incorporated's (INSM) CEO Will Lewis on Q3 2021 Results - Earnings Call Transcript

Insmed (INSM) delivered earnings and revenue surprises of -15.66% and -2.77%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) Reports Q3 Loss, Lags Revenue Estimates

BRIDGEWATER, N.J., Oct. 28, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the third quarter ended September 30, 2021 and provided a business update.

Insmed Reports Third Quarter 2021 Financial Results and Provides Business Update

Analysts Estimate Insmed (INSM) to Report a Decline in Earnings: What to Look Out for

BRIDGEWATER, N.J., Oct. 14, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third quarter 2021 financial results on Thursday, October 28, 2021.

Insmed to Host Third Quarter 2021 Financial Results Conference Call on Thursday, October 28, 2021

The shares of Insmed Incorporated (NASDAQ: INSM) have received a $60 price target from Cantor Fitzgerald. These are the details.

INSM Stock: $60 Price Target From Cantor Fitzgerald

BRIDGEWATER, N.J., Sept. 1, 2021 /PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following virtual investor events: Citi's 16th Annual BioPharma Virtual Conference on September 8, 2021 at 9:45 a.m.

Insmed To Participate in Five September Conferences

Insmed Inc. (INSM) CEO Will Lewis on Q2 2021 Results - Earnings Call Transcript

Insmed (INSM) has been struggling lately, but the selling pressure may be coming to an end soon.

Insmed (INSM) Sees Hammer Chart Pattern: Time to Buy?

BRIDGEWATER, N.J., Aug. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a business update.

Insmed Reports Second Quarter 2021 Financial Results and Provides Business Update

Earnings Preview: Insmed (INSM) Q2 Earnings Expected to Decline

Insmed (INSM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Here's Why Insmed (INSM) is Poised for a Turnaround After Losing 19.5% in 4 Weeks

BRIDGEWATER, N.J., July 27, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second quarter 2021 financial results on Thursday, August 5, 2021.

Insmed to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021

BRIDGEWATER, N.J., May 25, 2021 /PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following virtual investor events: The Jefferies Virtual Healthcare Conference on June 1, 2021 at 9:00 a.m.

Insmed To Present at Two June Conferences

BRIDGEWATER, N.J., May 19, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported data from a total of nine posters and oral presentations across its three programs—ARIKAYCE, brensocatib, and treprostinil palmitil inhalation powder (TPIP)—at the virtual American Thoracic Society (ATS) 2021 International Conference.

News for Insmed Stock (INSM)